The Apex Times
Above the Noise
Business Wire
BusinessMastercard tests whether payment networks can tell humans from autonomous softwareThe Apex TimesBusinessNike shares slide 44% over a year as investors question whether the pullback outlines a bargainThe Apex TimesBusinessCaterpillar pledges up to $10 million to expand workforce training in North CarolinaThe Apex TimesBusinessMicrosoft pulls back from UK data-center deal, hurting Nscale’s IPO hopes, Telegraph reportsThe Apex TimesBusinessOpinion piece weighs Chevron free-cash-flow strength against Realty Income’s long dividend streakThe Apex TimesBusinessGE Aerospace shares rise 5% over a year, trading well below its August recordThe Apex TimesBusinessAhead of Big Earnings Week, Meta’s Report and Tesla’s Results Loom Over Market SentimentThe Apex TimesBusinessNetflix shares show a recurring late-year pattern, but October volatility remains a watch pointThe Apex TimesBusinessCoca-Cola shares rise 39% in a year as KFC deal boosts beverage visibilityThe Apex TimesBusinessAlphabet investors weigh a bullish “double by 2030” scenario as debate returns to AI, ad resilience, and valuationThe Apex TimesBusinessMicrosoft withdraws from planned UK data-centre partnership with Nscale, Telegraph reportsThe Apex TimesBusinessDividend debate turns to PepsiCo after outlook trim, while Verizon remains a rival income pickThe Apex TimesBusinessMastercard tests whether payment networks can tell humans from autonomous softwareThe Apex TimesBusinessNike shares slide 44% over a year as investors question whether the pullback outlines a bargainThe Apex TimesBusinessCaterpillar pledges up to $10 million to expand workforce training in North CarolinaThe Apex TimesBusinessMicrosoft pulls back from UK data-center deal, hurting Nscale’s IPO hopes, Telegraph reportsThe Apex TimesBusinessOpinion piece weighs Chevron free-cash-flow strength against Realty Income’s long dividend streakThe Apex TimesBusinessGE Aerospace shares rise 5% over a year, trading well below its August recordThe Apex TimesBusinessAhead of Big Earnings Week, Meta’s Report and Tesla’s Results Loom Over Market SentimentThe Apex TimesBusinessNetflix shares show a recurring late-year pattern, but October volatility remains a watch pointThe Apex TimesBusinessCoca-Cola shares rise 39% in a year as KFC deal boosts beverage visibilityThe Apex TimesBusinessAlphabet investors weigh a bullish “double by 2030” scenario as debate returns to AI, ad resilience, and valuationThe Apex TimesBusinessMicrosoft withdraws from planned UK data-centre partnership with Nscale, Telegraph reportsThe Apex TimesBusinessDividend debate turns to PepsiCo after outlook trim, while Verizon remains a rival income pickThe Apex TimesBusinessMastercard tests whether payment networks can tell humans from autonomous softwareThe Apex TimesBusinessNike shares slide 44% over a year as investors question whether the pullback outlines a bargainThe Apex TimesBusinessCaterpillar pledges up to $10 million to expand workforce training in North CarolinaThe Apex TimesBusinessMicrosoft pulls back from UK data-center deal, hurting Nscale’s IPO hopes, Telegraph reportsThe Apex TimesBusinessOpinion piece weighs Chevron free-cash-flow strength against Realty Income’s long dividend streakThe Apex TimesBusinessGE Aerospace shares rise 5% over a year, trading well below its August recordThe Apex TimesBusinessAhead of Big Earnings Week, Meta’s Report and Tesla’s Results Loom Over Market SentimentThe Apex TimesBusinessNetflix shares show a recurring late-year pattern, but October volatility remains a watch pointThe Apex TimesBusinessCoca-Cola shares rise 39% in a year as KFC deal boosts beverage visibilityThe Apex TimesBusinessAlphabet investors weigh a bullish “double by 2030” scenario as debate returns to AI, ad resilience, and valuationThe Apex TimesBusinessMicrosoft withdraws from planned UK data-centre partnership with Nscale, Telegraph reportsThe Apex TimesBusinessDividend debate turns to PepsiCo after outlook trim, while Verizon remains a rival income pickThe Apex TimesBusinessMastercard tests whether payment networks can tell humans from autonomous softwareThe Apex TimesBusinessNike shares slide 44% over a year as investors question whether the pullback outlines a bargainThe Apex TimesBusinessCaterpillar pledges up to $10 million to expand workforce training in North CarolinaThe Apex TimesBusinessMicrosoft pulls back from UK data-center deal, hurting Nscale’s IPO hopes, Telegraph reportsThe Apex TimesBusinessOpinion piece weighs Chevron free-cash-flow strength against Realty Income’s long dividend streakThe Apex TimesBusinessGE Aerospace shares rise 5% over a year, trading well below its August recordThe Apex TimesBusinessAhead of Big Earnings Week, Meta’s Report and Tesla’s Results Loom Over Market SentimentThe Apex TimesBusinessNetflix shares show a recurring late-year pattern, but October volatility remains a watch pointThe Apex TimesBusinessCoca-Cola shares rise 39% in a year as KFC deal boosts beverage visibilityThe Apex TimesBusinessAlphabet investors weigh a bullish “double by 2030” scenario as debate returns to AI, ad resilience, and valuationThe Apex TimesBusinessMicrosoft withdraws from planned UK data-centre partnership with Nscale, Telegraph reportsThe Apex TimesBusinessDividend debate turns to PepsiCo after outlook trim, while Verizon remains a rival income pickThe Apex Times
Back to front
Lilly reports 52-week Phase 3b results combining Taltz and Zepbound in adults with psoriatic disease and obesity
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 31, 7:21 AM EDT

Lilly reports 52-week Phase 3b results combining Taltz and Zepbound in adults with psoriatic disease and obesity

New 52-week readouts from Lilly’s TOGETHER-PsO and TOGETHER-PsA trials add one-year data on the concomitant use of its ixekizumab and tirzepatide treatments in patients with psoriatic conditions and excess weight.

By The Apex Times Newsroom3 min readAI-assisted Apex article

Eli Lilly and Co. said it has generated 52-week results from two open-label Phase 3b studies testing whether its Taltz and Zepbound can be used together in adults living with psoriatic disease and obesity. The company said the one-year data show improved and durable efficacy, as presented in an announcement carried by Yahoo Finance on Aug. 31.

Taltz is the brand name for ixekizumab, a biologic medicine used to treat several immune-mediated inflammatory conditions. Zepbound is tirzepatide, an injectable medicine originally developed for metabolic disease and also used in obesity management through its effects on appetite and blood-sugar pathways. Lilly’s trial concept pairs the anti-inflammatory mechanism of ixekizumab with the weight and metabolic effects of tirzepatide.

The studies, which Lilly described as TOGETHER-PsO and TOGETHER-PsA, evaluate the concomitant use of Taltz and Zepbound in adults with psoriatic disease and obesity. TOGETHER-PsO is aimed at psoriatic disease with obesity, while TOGETHER-PsA focuses on psoriatic arthritis. Both programs are described as novel open-label Phase 3b studies, meaning all participants receive the combination and results are observed over time rather than through blinded comparison arms.

Lilly characterized the 52-week findings as “improved and durable efficacy” at the one-year mark. The Yahoo Finance posting, as summarized in the provided material, did not include specific numerical outcomes, response rates, or comparative statistics in the text available here, so it is not possible to independently verify the magnitude of improvement from the information at hand.

The company’s interest in a paired regimen reflects a growing clinical and commercial focus on treating comorbid conditions together. Psoriatic disease affects both joints and skin in many patients, and excess weight is common in this population. By combining an immune-targeted therapy with an obesity and metabolic therapy, Lilly is probing whether controlling inflammation and body weight simultaneously could improve long-term disease control.

Sector context matters because tirzepatide-based medicines have expanded the obesity market and raised expectations for durable benefits beyond weight reduction, while psoriasis and psoriatic arthritis biologics remain competitive in inflammatory disease. If Lilly can demonstrate sustained improvements in patients with both conditions, it could support differentiated prescribing patterns that treat obesity as part of the overall disease burden rather than a separate target.

Still, there are gaps in what is disclosed in the summarized announcement. In the provided text, Lilly does not specify key endpoints, safety indicates, dosing schedules, subgroup results, or whether outcomes were assessed with standardized disease activity measures at 52 weeks. Without those details, it is unclear how the company’s results compare with what would be expected from each drug’s established monotherapy performance in similar populations.

For now, investors and clinicians will likely focus on what Lilly chooses to publish next, including the full 52-week dataset, safety details for the combination, and how the outcomes align with regulators’ expectations for Phase 3 evidence. A further readout could also clarify whether the company plans to advance the approach into later-stage studies and whether it will target specific patient groups within psoriatic disease and obesity.

Why It Matters

  • If Lilly can substantiate sustained disease improvements in a comorbid population, it could strengthen the case for integrated treatment strategies in psoriatic disease.
  • The results, if backed by full datasets, could shape how payers and clinicians think about combining biologics with obesity medicines in practice.
  • The one-year readout adds timing evidence that may be important for durability claims, though the magnitude and clinical relevance depend on endpoints not included in the summarized text.
  • The program also indicates Lilly’s intent to broaden tirzepatide’s positioning beyond obesity into adjacent inflammatory disease settings.

Sources

Key Facts

  • Eli Lilly announced 52-week (one-year) results from two open-label Phase 3b trials evaluating concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide).
  • The trials are TOGETHER-PsO and TOGETHER-PsA, aimed at adults with psoriatic disease and obesity, including psoriatic arthritis in TOGETHER-PsA.
  • Lilly said the one-year results showed improved and durable efficacy for the combination.
  • Taltz is ixekizumab, an immune-targeted biologic used for inflammatory conditions; Zepbound is tirzepatide, an injectable medicine used for obesity management via metabolic effects.
  • The provided Yahoo Finance text summary does not include specific numeric efficacy outcomes or detailed safety disclosures.

Healthcare Related

Lilly reports 52-week Phase 3b results combining Taltz and Zepbound in adults with psoriatic disease and obesity | The Apex Times